PROLOR Biotech

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is the primary focus of PROLOR Biotech's product development?

PROLOR Biotech focuses on developing longer-acting versions of existing therapeutic proteins and peptide drugs, aiming to reduce the frequency of administration, such as weekly injections instead of daily.

What medical conditions do PROLOR Biotech's primary products target?

PROLOR Biotech's three primary products are designed to treat growth hormone deficiency, hemophilia, and type 2 diabetes.

When was PROLOR Biotech founded?

PROLOR Biotech was founded in January 2005.

When did PROLOR Biotech become a publicly traded company?

PROLOR Biotech completed an IPO in March 2010, listing on AMEX.

What was the status of PROLOR Biotech as of August 2013?

In August 2013, PROLOR Biotech was acquired by OPKO Health for approximately $480 million and subsequently became inactive as an independent entity.

What was PROLOR Biotech's employee count at the time of its acquisition?

PROLOR Biotech had an employee count of 31, falling within the 11-50 employee range.

What is the current operational status of PROLOR Biotech?

PROLOR Biotech is currently inactive, having been acquired by OPKO Health in August 2013.

What did OPKO Health do with PROLOR Biotech after the acquisition?

According to an April 2014 report, OPKO Health transformed PROLOR Biotech into its Israeli R&D and investment arm.

Sectors & technology

Tags